Medela AG
$14.7K 20 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Aytu BioPharma, Inc.
Aytu BioPharma, Inc. reported $14,745.49 across General Payments, Research, and Ownership to 873 physicians and teaching hospitals across 873 transactions.
- $14.7K Below-median payer
- All-tracks total
- 873 Above-median volume
- Transactions
- 873 Above-median reach
- Recipients
- +$3.8K
- General Payments vs PY2023
Aytu BioPharma, Inc. reported $14,745.49 across all CMS Open Payments tracks (General + Research + Ownership) to 873 physicians and teaching hospitals in Program Year 2024 - ranking #1579 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $14,745.49, averaging $16.89 per recipient.
Aytu BioPharma, Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
13/100
Total payments
F
10/100
Transaction volume
F
16/100
Physician reach
F
17/100
Payment type diversity
F
10/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer aytu-biopharma-inc Aytu BioPharma, Inc.
$14.7K · #1579/1,925 · 0.0% industry · PY2024
- TOT $14.7K
- RANK #1579
- SHARE 0.0%
- TXN 873
- RCP 873
- CAT 1
- GEN $14.7K
- ΔGEN +$3.8K
- TOP1 0.5%
- PY 2024
Volume peers
Nearest volume peer: Medela AG ($14.7K)
Aytu BioPharma, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Aytu BioPharma, Inc.'s CMS-reported General Payments increased by $3.8K (+34.5%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: AYTU BIOPHARMA, INC.PY2023: AYTU BIOPHARMA, INC.PY2024: Aytu BioPharma, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $10,959.15
- PY2024
- $14,745.49
What the Data Shows for Aytu BioPharma, Inc.
The all-tracks total above combines three CMS reporting categories - General Payments, Research Payments, and Ownership/Investment interests - not one undifferentiated figure. For Aytu BioPharma, Inc. that figure is drawn almost entirely from the General Payments track (day-to-day consulting, meals, travel and speaking fees). CMS publishes each Program Year's data roughly 12 months after the reporting period ends, so this reflects the most recently released cycle; see our methodology for how the tracks are standardized and compared across companies.
"Food and Beverage" leads the 1-category general-payment breakdown below at $14.7K (100.0% of General Payments, 873 transactions) - see our methodology for how research and ownership payments are reported separately.
General Payment Breakdown by Type
Aytu BioPharma, Inc. made 1 types of general payments. "Food and Beverage" is the largest category at $14.7K, 100.0% of General Payments.
How Aytu BioPharma, Inc. divides its payments
How the reported total splits across payment categories
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Food and Beverage | $14.7K | 873 | 100.0% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $363.65 (2.5%) of $14,745.49 in this company's General Payments records across 718 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Aytu BioPharma, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Jennifer Caicedo
$79.84 across 4 reported transactions
- 2
Hannah Mules
$70.96 across 4 reported transactions
- 3
Cathy Gvozden
$70.95 across 4 reported transactions
- 4
Andre Gvozden
$70.95 across 4 reported transactions
- 5
Eliza Huebner
$70.95 across 4 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Aytu BioPharma, Inc. ranks #1579 of 1,925 by total payments (bottom 18% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,822 of 1,838 by HHI (bottom 1% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- Valinor Pharma, LLC : $65.8K total payments, HHI 20
- Regeneron Healthcare Solutions, Inc. : $24.7M total payments, HHI 19
- GlaxoSmithKline, LLC. : $26.4M total payments, HHI 18
- Intuitive Surgical, Inc. : $74.2M total payments, HHI 18
- RedHill Biopharma Inc. : $37.3K total payments, HHI 18
- Kestra Medical Technology Services, Inc. : $515.4K total payments, HHI 17
- Aytu BioPharma, Inc. (this company) : $14.7K total payments, HHI 17
- Lilly USA, LLC : $46.6M total payments, HHI 16
- 180 Medical, Inc. : $86.9K total payments, HHI 13
- Janssen Biotech, Inc. : $30.9M total payments, HHI 13
- Amphastar Pharmaceuticals, Inc. : $41.3K total payments, HHI 13
- E.R. Squibb & Sons, L.L.C. : $31.0M total payments, HHI 12
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Aytu BioPharma, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Aytu BioPharma, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Aytu BioPharma, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Celltrion Healthcare Canada Ltd.
$14.7K 6 recipients
Compare payment profiles
Kub Technologies Inc.
$14.7K 131 recipients
Compare payment profiles
Les Laboratoires Servier
$14.8K 5 recipients
Compare payment profiles
Retropsoas Technologies, LLC
$14.6K 12 recipients
Compare payment profiles
North American Rescue, LLC
$14.6K 8 recipients
Compare payment profiles
Put this to use
Aytu BioPharma, Inc. ranks #1579 of 1,925 by all-tracks total payments, led by "Food and Beverage".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Food and Beverage" spend across every manufacturer, not just Aytu BioPharma, Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.